

Phase 2, multicenter, open-label basket trial of *nab*-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in *TSC1* or *TSC2* genes (PRECISION I)


Gopa Iyer, MD¹; Michael J. Demeure, MD²; Dustin Deming, MD³; Noah Federman, MD⁴; Meredith A. McKean, MD⁵; Elizabeth K. Lee, MD⁶; Alexander Spira, MD, PhD⁷; David J. Kwiatkowski, MD, PhD⁸; Maen A. Hussein, MD⁹; Erlinda M. Gordon, MD¹⁰; David G. Crockett, MD¹¹; Kristen N. Ganjoo, MD¹²; Brian Schulte, MD¹³; Lee D. Cranmer, MD, PhD¹⁴; Anita N. Schmid, PhD¹⁵; Willis H. Navarro, MD¹⁵; Loretta M. Itri, MD¹⁵; Jordi Rodon Ahnert, MD, PhD¹⁶

¹Memorial Sloan Kettering Cancer Center, New York, NY; ²Hoag Memorial Hospital Presbyterian, Newport Beach, CA; ³University of Wisconsin, Madison, WI; ⁴University of California, Los Angeles, CA; ⁵Sarah Cannon and HCA Research Institute, Nashville, TN; ⁶Dana-Farber Cancer Institute, Boston, MA; ⁷Virginia Cancer Specialists, Fairfax, VA; ⁸Brigham and Women's Hospital, Boston, MA; ⁹Florida Cancer Specialists North Division, St. Petersburg, FL; ¹⁰Sarcoma Oncology Research Center, Santa Monica, CA; ¹¹Nebraska Cancer Specialists, Omaha, NE; ¹²Stanford Cancer Center, Stanford, CA; ¹³UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; ¹⁴University of Washington, Fred Hutchinson Cancer Center, Seattle, WA; ¹⁵Aadi Bioscience, Pacific Palisades, CA; ¹⁶MD Anderson Cancer Center, Houston, TX

INTRODUCTION

- Tuberous sclerosis complex subunit 1 or 2 (*TSC1* or *TSC2*) are critical negative regulators of mechanistic target of rapamycin (mTOR) complex 1 activation¹ (Figure 1)

Figure 1. PI3K-Akt-mTOR pathway



4EBP1, eukaryotic translation initiation factor 4E-binding protein; Akt, protein kinase B; Erk, extracellular signal-regulated kinase; Mek, mitogen-activated protein kinase kinase; mTOR, mechanistic target of rapamycin; mTORC1, mTOR complex 1; *nab*, nanoparticle albumin-bound; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; Raf, rapidly accelerated fibrosarcoma; Raptor, regulatory-associated protein of mTOR; Ras, rat sarcoma virus homolog; Rheb, Ras homolog enriched in brain; S6K, ribosomal S6 kinase; *TSC1/TSC2*, tuberous sclerosis complex subunit 1 or 2.

- Inactivating alterations in *TSC1* and/or *TSC2* have been observed in several types of cancer, but there are currently no approved treatment options for these patients (Table)


Table. Estimated incidence of patients with definite impact *TSC1* or *TSC2* alterations

Tumor type	Definite impact <i>TSC1</i> mutations ^a	Definite impact <i>TSC2</i> mutations ^a	Eligible <i>TSC1</i> or <i>TSC2</i> combined
Bladder	6.33%	1.70%	8.03%
Hepatobiliary	1.27%	3.31%	4.58%
Endometrial	2.10%	1.22%	3.32%
Soft tissue sarcoma	1.28%	1.71%	2.99%
Ovarian	1.85%	0.92%	2.77%
Esophagogastric	0.65%	1.46%	2.11%
Kidney	1.51%	0.45%	1.96%
NSCLC	0.77%	1.16%	1.93%
Melanoma	1.14%	0.68%	1.82%
CRC	0.99%	0.39%	1.38%
Thyroid	0.83%	—	0.83%
Cervix	—	0.71%	0.71%
Pancreatic	0.57%	—	0.57%
Breast	0.41%	0.10%	0.51%

^aThe proportion of patients with definite impact alterations (ie, alterations known to have a biological impact; this includes frameshift, nonsense, and splice-site alterations and deep deletions) was derived from the NIH NCI Genomic Data Commons Data Portal (NIH NCI Genomic Data Commons). CRC, colorectal carcinoma; NCI, National Cancer Institute; NIH, National Institutes of Health; NSCLC, non-small cell lung cancer; *TSC1*, tuberous sclerosis complex subunit 1; *TSC2*, tuberous sclerosis complex subunit 2.

- The utility of oral mTOR inhibitors, such as sirolimus as pan-cancer agents, may be restricted by low bioavailability and dose-limiting toxicity^{2,3}
- To improve the pharmacologic properties of sirolimus, *nab*-sirolimus, a nanoparticle form of human albumin-bound sirolimus, was developed for intravenous (IV) use
- In preclinical animal models, *nab*-sirolimus demonstrated significantly **A)** higher intratumor drug concentrations, **B)** greater tumor growth inhibition, **C)** improved survival, and **D)** greater inhibition of the downstream marker of mTOR activity, phosphorylated-S6 (pS6) ribosomal protein, relative to equal weekly doses of sirolimus and everolimus (Figure 2)


Figure 2. (A) Intratumor drug concentration, (B) tumor growth inhibition, (C) survival, and (D) mTOR activity



AUC, area under the curve; IV, intravenous; *nab*, nanoparticle albumin-bound; PO, per os (orally); pS6, ribosomal protein S6.

- nab*-Sirolimus is approved in the US for the treatment of adult patients with locally advanced, unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)⁴ based on clinical efficacy and safety results from the AMPECT trial (NCT02494570)⁵

Figure 3. Percent change in target tumor measurements




- An exploratory biomarker analysis from AMPECT demonstrated that known inactivating alterations in *TSC1* or *TSC2* were associated with response to *nab*-sirolimus in PEComa, suggesting *nab*-sirolimus might be beneficial for patients with other solid tumors harboring *TSC1* or *TSC2* alterations (Figure 3)⁵
- Most treatment-emergent adverse events (TEAEs) were grade 1/2 and were manageable for long-term treatment; no grade ≥4 treatment-related TEAEs were observed
- The overall safety profile was consistent with other mTOR inhibitors, with no new or unexpected safety signals emerging in the AMPECT trial
- Patients with various malignancies bearing *TSC1* or *TSC2* mutations treated with *nab*-sirolimus as part of the expanded access program (NCT03817515), showed evidence of response (partial response in 5/7 patients) and manageable toxicities⁶

- The phase 2 PRECISION I trial was initiated to evaluate the potential of mTOR inhibition with *nab*-sirolimus for the treatment of patients with solid tumors harboring *TSC1* or *TSC2* inactivating alterations

STUDY DESIGN

- PRECISION I (NCT05103358) is a prospective, phase 2, open-label, multi-institution basket trial to determine the efficacy and safety profile of *nab*-sirolimus in patients with malignant solid tumors with pathogenic inactivating alterations in *TSC1* (Arm A) or *TSC2* (Arm B)
- Partnerships with next-generation sequencing companies (Foundation Medicine, Tempus, and Caris) will help to identify eligible patients



^aCentral confirmation of *TSC1* and *TSC2* pathogenic inactivating alterations is via evaluation of NGS reports. Patients will be enrolled only after central confirmation of eligibility. Pathogenic inactivating alterations are defined as truncating alterations (nonsense, frameshift, splice, intragenic loss/deletion of ≥1 exons) or deletions (patients with 2-copy deletion in *TSC1/TSC2*).
^bDCR was defined as BOR of confirmed CR or PR (either of any duration) or stable disease ≥12 weeks following study treatment initiation by IRR. BOR, best overall response; CR, complete response; DCR, disease control rate; DOR, duration of response; IRR, independent radiographic review; IV, intravenous; *nab*, nanoparticle albumin-bound; NGS, next-generation sequencing; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; *TSC1/TSC2*, tuberous sclerosis complex subunit 1 or 2; TTR, time to response.

Key Inclusion Criteria

- ≥12 years of age
- Metastatic or locally advanced malignant solid tumor with a pathogenic inactivating *TSC1* or *TSC2* alteration, where surgical resection is not an option, or likely to result in severe morbidity
- Received appropriate standard treatments or be unlikely to tolerate or derive clinically meaningful benefit from standard therapy as determined by the investigator
- ECOG performance status of 0 or 1, KPS ≥80, or Lansky play-performance scale for pediatric patients ≥80
- ≥1 measurable target lesion by CT scan or MRI

Key Exclusion Criteria

- Prior treatment with mTOR inhibitor
- Recent infection requiring systemic anti-infective treatment
- Primary brain tumor or PEComa
- Severe and/or uncontrolled medical or psychiatric conditions prior to receiving the first dose of *nab*-sirolimus
- For patients on strong inhibitors, inducers, and known CYP3A4 substrates, discontinuation is required ≥5 half-lives

The full list of inclusion and exclusion criteria is available at <https://www.clinicaltrials.gov/ct2/show/NCT05103358>.
CT, computed tomography; CYP3A4, cytochrome P450 3A4; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky performance status; mTOR, mechanistic target of rapamycin; MRI, magnetic resonance imaging; *nab*, nanoparticle albumin-bound; PEComa, perivascular epithelioid tumor; *TSC1/TSC2*, tuberous sclerosis complex subunit 1 or 2.

SUMMARY

- Available data from the exploratory analysis and an expanded access program suggest acceptable efficacy and safety of *nab*-sirolimus, an mTOR inhibitor with enhanced antitumor activity, in patients with solid tumors harboring inactivating alterations in *TSC1* and/or *TSC2*
- PRECISION I is a registrational trial now recruiting for patients with solid tumors driven by *TSC1* or *TSC2* alterations, an underserved patient population with no targeted therapeutic options; this trial is designed to evaluate the efficacy, safety, and tolerability of *nab*-sirolimus

REFERENCES

- He Y, et al. *Signal Transduct Target Ther*. 2021;6(1):425. 2. Saxton RA, et al. *Cell*. 2017;169(2):361–71. 3. Pavavra F, et al. *Oxid Med Cell*. 2017;9820181. 4. FYARRO (sirolimus albumin-bound particles for injectable suspension). Package insert. Aadi Bioscience, Inc.: Pacific Palisades, CA; 2021. 5. Wagner AJ, et al. CTOS, November 10-13, 2021, Virtual. 6. Dickson MA, et al. ASCO, June 4-8, 2021, Virtual.

DISCLOSURES: GI, DD, MAK, EKL, DJK, EMG, DGC, and BS report no conflicts of interest. JRA reports research funding from Bayer and Novartis, and personal fees from Eli Lilly, Peptomyc, and Servier. MJD reports consulting fees from Bayer, Eli Lilly, On Cusp Therapeutics, and TD2. NF reports consulting and speakers' fees from Bayer. AS reports honoraria from ARIAD Pharmaceuticals, Clovis Oncology, Novartis, and Roche; consulting fees from ARIAD Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Genentech, and Roche; research funding from AbbVie, Astellas Pharma, AstraZeneca, BeiGene, Boehringer Ingelheim, Clovis Oncology, MedImmune, Merck, Merrimack, NewLink Genetics, Novartis, and Roche; and travel fees from ARIAD Pharmaceuticals and Roche. MAH reports consulting fees from Guardant Health; speakers' fees from AMAG Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Heron, Incyte, and Pfizer; and stock ownership in Celgene. KNG reports consulting fees from Daiichi Sankyo, Deciphera, Foundation Medicine. LDC reports research funding from Merck, and grant support and speakers' fees from Bristol Myers Squibb and Genentech. ANS, WHN, and LMI are employees of Aadi Bioscience, Inc. and own stock.

ACKNOWLEDGMENTS: This study was funded by Aadi Bioscience, Inc. Medical writing and editorial support were provided by Hilary Durbano, PhD, of AlphaBioCom, LLC, King of Prussia, PA, USA, and funded by Aadi Bioscience, Inc.